Paul Sohmer - BG Medicine President CEO, Director
| BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
CEO
Dr. Paul R. Sohmer, M.D., is President, Chief Executive Officer, Director of BG Medicine, Inc., since May 8, 2013. Dr. Sohmer served as President and Chief Executive Officer of ViracorIBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology, and infectious disease testing from January 2011 to September 2012. Prior to joining ViracorIBT Laboratories, from February 2009 to January 2011, Dr. Sohmer served as Chief Executive Officer of Orthocon, Inc., a company that develops, manufactures, markets, and sells implantable products designed to stop bone bleeding. From 2007 to 2009, Dr. Sohmer served on the RadPharm, Inc. Board of Directors, and from 2008 to 2009, he served as Chairman of the Board of Directors of Molecular Biometrics, Inc. Dr. Sohmer served as Interim CEO of Cylex, Inc. from January through March of 2008 and CEO of Pathway Diagnostics from May to September of 2008. From June 2000 to December 2006, Dr. Sohmer served as Chairman, President and Chief Executive Officer of TriPath Imaging, Inc. . From 1997 to 2000, Dr. Sohmer served as President and Chief Executive Officer of Neuromedical Systems, Inc. . From 1992 to 1996, Dr. Sohmer served as President and Chief Executive Officer of Genetrix, Inc., a genetic testing lab. From 1991 to 1992, Dr. Sohmer served as Vice President of Professional Services for Nichols Institute. From 1985 to 1991, Dr. Sohmer served as President and Chief Executive Officer of Pathology Institute, Inc., where he led the first commercial introduction of polymerase chain reaction for diagnosis of HIV and founded the Chiron Reference Laboratory since 2013.
| Age | 74 |
| Tenure | 11 years |
| Phone | 781 890 1199 |
| Web | https://www.bg-medicine.com |
BG Medicine Management Efficiency
The company has return on total asset (ROA) of (0.7595) % which means that it has lost $0.7595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.0264) %, meaning that it created substantial loss on money invested by shareholders. BG Medicine's management efficiency ratios could be used to measure how well BG Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Harrison Gross | Innovative Eyewear | 31 | |
| Jay Rosengarten | Innovative Eyewear | 64 | |
Management Performance
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 |
BG Medicine Leadership Team
Elected by the shareholders, the BG Medicine's board of directors comprises two types of representatives: BG Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGMD. The board's role is to monitor BG Medicine's management team and ensure that shareholders' interests are well served. BG Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BG Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Connor, Director | ||
| Harry Wilcox, Director | ||
| Stelios Papadopoulos, Independent Director | ||
| Aram Adourian, Chief Scientific Officer and Sr. VP | ||
| Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer | ||
| Jeffrey Luber, Director | ||
| Paul Sohmer, President CEO, Director | ||
| Noubar Afeyan, Founder | ||
| James OConnor, Independent Director |
BGMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BG Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.86) % | ||||
| Current Valuation | 545.97 K | ||||
| Shares Outstanding | 11.37 M | ||||
| Number Of Shares Shorted | 630.05 K | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.35 X | ||||
| Revenue | 1.57 M | ||||
| Gross Profit | 1.06 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BG Medicine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BG Medicine's short interest history, or implied volatility extrapolated from BG Medicine options trading.
Pair Trading with BG Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BG Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BG Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against BGMD Pink Sheet
| 0.58 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.53 | DOMH | Dominari Holdings | PairCorr |
| 0.47 | YS | YS Biopharma | PairCorr |
The ability to find closely correlated positions to BG Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BG Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BG Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BG Medicine to buy it.
The correlation of BG Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BG Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BG Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BG Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |